Genetic Technologies Ltd. ADR (GENE) News
Filter GENE News Items
GENE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GENE News Highlights
- For GENE, its 30 day story count is now at 3.
- Over the past 24 days, the trend for GENE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about GENE are ASX.
Latest GENE News From Around the Web
Below are the latest news stories about Genetic Technologies Ltd that investors may wish to consider to help them evaluate GENE as an investment opportunity.
BelHealth Completes Asset Sale of General Genetics Corp.September 9, 2021–BelHealth Investment Partners, LLC ("BelHealth") is pleased to announce that it has completed the sale of assets of the international division of General Genetics Corporation (GGC), a provider of relationship and clinical genetic testing services, to Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company ("GTG"). The transaction was structured in a combination of cash and stock of GTG. |
Genetic Technologies Reports FY21 Results as it Turns the Corner on its Commercialization StrategyCompany to present at H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021MELBOURNE, Australia, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in Genomics based tests in health, wellness and serious disease, is pleased to provide the financial results for the year ended June 30, 2021. Highlights Revenues from customers of A$120k including receipt of first month sales from |
Genetic Technologies Enters Multi-Billion-Dollar Consumer Genomics MarketEasyDNA Acquisition Accelerates Global Expansion PlansMELBOURNE, Australia, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in Genomics based tests in health, wellness and serious disease, is pleased to announce the completion of its acquisition of EasyDNA (‘the acquisition’) for US$4 million in cash and stock on August 13, 2021. Overview BelHealth becomes a shareholder of Genetic Technologies with 2.3% holding following |
Genetic Technologies Rapidly Accelerating Commercialization PlansMELBOURNE, Australia, July 26, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”, “GTG”), a global leader in Genomics based tests in health, wellness and serious disease, is pleased to provide its Quarterly Business Update to the market. Highlights Revenues from customers of A$99k in the quarter (unaudited), up from A$6k in Q3, including receipt of first month IBX salesConfirmed launch of COVID-19 Risk Test by Infinity Biologix in the USConfirmed grant of US Patent N |
Genetic Technologies Acquires EasyDNA To Expand Into Wellness TestingGenetic Technologies Limited (NASDAQ: GENE) has agreed to acquire EasyDNA's brand and distribution rights from BelHealth for $4 million in cash and stock. EasyDNA currently sells paternity, oncology, and health & wellness genomics-based laboratory tests through agreements with 12 laboratories in North America, AsiaPac, and Europe. In CY20, EasyDNA had total revenue of $4.63 million through online retail sales of its at-home DNA tests. Under the terms of the agreement, the deal consideration comp |
Genetic Technologies Strengthens Global Leadership in Genomics with Acquisition of EasyDNAA global platform to market the Company’s portfolio across 40 countriesMELBOURNE, Australia, July 19, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in Genomics tests in health, wellness and serious disease, has signed an agreement to acquire the direct-to-consumer eCommerce business and distribution rights associated with General Genetics Corporation (GGC) and its associated brands trading as EasyDNA (‘EasyDNA’ or ‘EasyDNA Acqui |
Genetic Technologies Continues to Break New Ground as it Advances Development of its Predictive Risk Test for Multiple Cancers & MorbiditiesMELBOURNE, Australia, July 09, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE, "Company", "GTG"), a diversified Genomics and AI driven preventative health business, today announced updates on the development of its Predictive Panel Risk Test designed to cover six different cancers including breast and colorectal cancer, prostate and ovarian cancer, pancreatic cancer and melanoma. Key Highlights: Predictive Panel Risk Test to cover six common cancers which account f |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWelcome back, traders! |
US Patent Office Grants Foundational Pharmacogenomic PatentMELBOURNE, Australia, June 11, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business, has been granted US Patent No. 11,031,098 – ‘Computer Systems and Methods for Genomic Analysis’. The patent application was submitted in 2016, building on a patent family dating back to 2001 and was recently granted to Genetic Technologies and demonstrates an important addition to Genetic Technologies p |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWelcome back, investors! |